Detecting VRE: Swab Collection and Lab Techniques Explained

Detecting vancomycin-resistant enterococci, commonly called VRE, relies on a chain of steps that starts with a simple rectal swab and ends with laboratory confirmation of both the organism and its resistance genes. The process sounds straightforward, but each link in that chain carries its own quirks, tradeoffs, and failure points. Getting a reliable result depends on how the swab is collected, how it is transported, which culture media the lab chooses, and whether molecular methods are used alongside or instead of traditional growth-based techniques.

Why Rectal Swabs Are the Standard

Enterococci live harmlessly in the gastrointestinal tract of most people. When someone carries a vancomycin-resistant strain, the bacteria are shed in stool, which makes the rectum the most practical sampling site. In clinical practice, a moistened swab is inserted a few centimeters past the anal sphincter, rotated gently, and withdrawn. Perianal swabs, where the tip is simply pressed against the skin around the anus, are sometimes used as a less invasive alternative, though they tend to pick up fewer organisms.

A head-to-head comparison of rectal swabs and stool samples tested with a real-time PCR assay found that rectal swabs achieved about 98% sensitivity while stool samples reached about 95%, with no statistically significant difference between the two. Specificity was comparable as well, hovering around 87% for both specimen types.¹ So if a patient cannot tolerate a rectal swab, a fresh stool specimen works almost as well. Most hospitals prefer the swab because it is faster, less messy, and easier to standardize across nursing staff.

Getting the Specimen to the Lab

Once collected, the swab needs to survive the journey to the microbiology laboratory without losing the organisms on it. A common worry is that delays in transport, especially at room temperature, might let bacteria die off and produce a false-negative result. Research on this question has been reassuring. VRE transported in liquid Amies medium, a standard swab transport solution, survived up to 14 days at both room temperature and refrigerated conditions without any drop in recovery.² That is a generous window. In practice, most hospital specimens reach the lab the same day, so transport-related failure is rare as long as a proper collection system is used.

What matters more than speed is the medium itself. Dry swabs without transport medium can desiccate quickly and kill fastidious organisms. Liquid Amies tubes keep the bacteria viable without letting them multiply, which prevents overgrowth by competing flora. If your facility sends specimens to a reference lab by courier, the 14-day survival window means even multi-day shipping should not compromise results.

Culture-Based Detection

Traditional culture remains the backbone of VRE detection in most clinical laboratories, and the media choices have evolved considerably over the years. The classic approach uses bile esculin azide agar supplemented with vancomycin, often abbreviated BEAV. Enterococci break down esculin in the presence of bile, turning the agar dark brown or black, while the vancomycin in the medium suppresses susceptible strains and lets only resistant ones grow. BEAV is cheap and widely available, but it has limitations: some non-enterococcal organisms can also darken the medium, and sensitivity at the 24-hour read can be modest.

Adding a broth enrichment step before plating significantly improves yield. In one study comparing direct plating on bile esculin azide agar to a broth-first workflow, the enrichment step detected roughly 55% more VRE isolates from fecal specimens.³ The broth allows low-abundance VRE to multiply overnight before being transferred to selective agar, boosting the odds of a positive result. The tradeoff is an extra day of turnaround time.

Chromogenic agars offer a more modern alternative. These plates contain enzyme substrates that produce a visible color change when specific enterococcal species grow on them, making it easier to distinguish true VRE from look-alikes. One such product, a chromogenic VRE plate, achieved 99% sensitivity and about 95% specificity for detecting vancomycin-resistant E. faecium and E. faecalis, outperforming standard BEAV agar.⁴ A separate comparison found that a different chromogenic agar hit 98% sensitivity and 95% specificity at 24 hours, which was significantly better than BEAV’s 86% sensitivity at the same time point.⁵ That difference matters when infection-control teams need fast answers to decide whether a newly admitted patient should be placed in contact precautions.

A newer hybrid approach combines BEAV broth with MALDI-TOF mass spectrometry, a technology that identifies bacteria by their protein profile. The idea is to use the sensitive broth step for enrichment and then skip traditional subculture by running the broth contents directly through MALDI-TOF for rapid species confirmation.⁶ This can shave hours off the identification timeline while maintaining the sensitivity advantages of broth enrichment.

Phenotypic Susceptibility Testing

Once a colony grows on selective media, the laboratory still needs to confirm that the organism is genuinely resistant to vancomycin and determine the level of resistance. This is where susceptibility testing comes in. The reference methods are broth microdilution and agar dilution, both of which measure the minimum inhibitory concentration (MIC), the lowest concentration of vancomycin that stops the bacteria from growing. An MIC above a certain threshold confirms resistance.

Automated commercial systems and gradient diffusion strips generally agree well with these reference methods for high-level resistance. An evaluation of ten commercial susceptibility platforms found that broth-based systems and the gradient strip method all produced no major classification errors when tested against reference broth microdilution.⁷ Where things get dicier is at the low end of resistance. Isolates with MICs just above the susceptibility breakpoint, or those with intermediate resistance, can be misclassified depending on the testing method. A proficiency study of Spanish laboratories found that a high-level resistant strain was correctly flagged about 91% of the time, but an isolate with intermediate-level resistance was caught only 50% of the time.⁸ This is a real-world problem, because missing low-level resistance means a patient could be treated with vancomycin when it will not work, and the resistant strain can continue spreading unnoticed.

A faster colorimetric approach uses a dye called resazurin that changes color from blue to pink when bacteria are metabolically active. By adding the dye to vancomycin-containing broth, a technician can visually read the MIC in as little as four hours, compared to the 18 to 24 hours needed for standard broth microdilution. Testing against 80 enterococcal isolates showed perfect agreement with the reference methods.⁹ While not yet widely adopted, this kind of shortcut is attractive in settings where every hour of delay in result reporting translates to broader antibiotic exposure and harder infection-control decisions.

Molecular Methods for Direct Detection

The fastest route to a VRE result bypasses culture entirely and goes straight to detecting resistance genes in the swab sample. Vancomycin resistance in clinically important enterococci is encoded primarily by two gene clusters, vanA and vanB. PCR-based assays that target these genes can return results in one to two hours from specimen receipt, compared to the 24 to 72 hours needed for culture-based workflows.

Several commercial platforms perform this work with minimal hands-on time. The BD GeneOhm VanR assay, for instance, integrates DNA extraction and amplification into a single automated process, targeting both vanA and vanB sequences from perianal or rectal swabs.¹⁰ High-throughput alternatives now run on large analyzers that can process hundreds of samples in a shift, making it feasible to screen entire hospital wards during an outbreak. One validation study of a quantitative vanA/vanB assay on a high-throughput system found 100% sensitivity for both gene targets compared to a cartridge-based reference system, though vanB specificity was somewhat lower at about 92%, reflecting a known issue with vanB-like sequences found in non-enterococcal gut bacteria.¹¹

That vanB specificity issue deserves a closer look. The vanB gene has relatives in common gut anaerobes that are not enterococci and are not clinically relevant. When a PCR assay picks up these environmental vanB sequences, the result is a molecular positive that does not correspond to an actual VRE carrier. This is one reason many laboratories still pair molecular screening with reflex culture: a positive PCR triggers a culture to confirm a live, resistant enterococcal organism is truly present. The molecular test gets you speed; the culture gives you certainty.

The VanC Complication

Not all vancomycin resistance in enterococci is created equal, and the species carrying vanC genes are a common source of confusion. Enterococcus gallinarum and E. casseliflavus naturally carry vanC-type genes that confer low-level intrinsic resistance to vancomycin. These organisms are rarely involved in serious infections and are not the VRE that infection-control programs worry about. The concern is that they can trip up screening workflows.

On culture media containing vancomycin, vanC-carrying species may grow and darken bile esculin plates just like clinically important VRE. If the lab does not identify the species, it can report a false alarm, leading to unnecessary isolation precautions. Molecular assays designed to detect only vanA and vanB genes will correctly ignore these organisms, but broader PCR panels or older assays that pick up vanC sequences can generate confusing results. One study found that among vancomycin-resistant E. gallinarum isolates, molecular screening was positive in half the cases, illustrating how PCR results must be interpreted alongside species identification.¹² PCR-based methods to distinguish vanC-1, vanC-2, and vanC-3 genes exist and can resolve ambiguous cases by tying the gene to the species.¹³

Species Identification With MALDI-TOF

Because knowing the species is just as important as knowing the resistance profile, modern laboratories lean heavily on MALDI-TOF mass spectrometry for rapid identification. The technology works by vaporizing a tiny smear of bacterial colony with a laser and analyzing the resulting protein fragments. Each species produces a characteristic mass spectrum, essentially a protein fingerprint, that gets matched against a reference database in seconds.

For enterococci, MALDI-TOF reliably distinguishes E. faecium, which accounts for most hospital VRE, from E. faecalis and the intrinsically resistant species like E. gallinarum. Studies applying MALDI-TOF to enterococcal isolates have found strong concordance with species-specific PCR confirmation.¹⁴ Research into the spectral details has even identified genus-specific peaks and species-level groupings that improve discrimination within the E. faecium group, which contains closely related species that older biochemical tests struggled to tell apart.¹⁵ In practical terms, MALDI-TOF has replaced the labor-intensive biochemical panels that used to take an extra day. A colony on a chromogenic plate in the morning can have a confirmed species name by lunchtime.

Quality Control and the Detection Gap

Even with good methods, laboratories can miss VRE if their processes are not regularly validated. External quality assessment programs, where reference laboratories send blinded samples to participating labs, reveal persistent detection gaps. A WHO-affiliated proficiency testing program found that most participating laboratories could detect high-level vancomycin resistance in E. faecium, but performance dropped with lower-resistance phenotypes.¹⁶

For molecular methods specifically, six years of external quality assessment data showed that labs detected vanA-positive samples at about 95% from the start and held steady, while detection of vanB-positive samples started lower at 82% but improved to above 90% in subsequent years as assays and training matured.¹⁷ The initial vanB gap likely reflected both technical challenges, such as cross-reactivity with non-enterococcal vanB sequences, and the fact that vanB-positive VRE circulate at lower levels in many regions, giving labs less routine experience with them. The improvement over time is encouraging and underscores why participation in proficiency programs is not just bureaucratic busywork but a genuine safeguard against missed cases.

Whole-Genome Sequencing for Outbreak Detection

Standard screening tells you whether a single patient carries VRE. Whole-genome sequencing goes further and tells you whether two patients’ VRE strains are related closely enough to suggest they were transmitted within the hospital. This distinction matters because VRE is common enough that multiple unrelated strains circulate simultaneously. Without genomic data, infection-control teams cannot tell a true outbreak from unrelated background colonization.

In one striking example, whole-genome sequencing surveillance of routine clinical isolates uncovered a cluster of ten genetically related VRE infections linked to interventional radiology procedures. The outbreak had not been recognized by standard surveillance methods.¹⁸ A broader evaluation at another institution found that adding rectal screening isolates to the genomic surveillance pool, rather than sequencing only isolates from patients with clinical infections, increased detection of transmission clusters from 53% to 67%.¹⁹ The message is clear: sequencing just the sickest patients’ isolates misses transmission chains that pass through silent carriers.

Whole-genome sequencing remains expensive and computationally demanding relative to PCR or culture. It is not a frontline screening tool. But for institutions with persistent VRE problems, it provides a level of resolution that no other method matches. As sequencing costs continue to fall, its role in routine surveillance is expanding.

Loop-Mediated Isothermal Amplification

Between traditional culture and expensive automated PCR systems, there is growing interest in simpler molecular methods that could work in resource-limited settings. Loop-mediated isothermal amplification, or LAMP, amplifies DNA at a single temperature using a water bath or heating block, eliminating the need for a thermal cycler. Results can be read with the naked eye: a color change or the appearance of a white precipitate signals a positive reaction.

Several groups have developed LAMP assays targeting the vanA and vanB genes. One early study showed that LAMP detected the vanA gene from clinical isolates within 40 minutes and was more sensitive than conventional PCR.²⁰ A multiplex LAMP assay targeting both vanA, vanB, and a general enterococcal gene showed 100% agreement with real-time PCR for the resistance genes across 86 VRE strains, with optimal performance at 65°C for 60 minutes.²¹ Another group reported sample processing, amplification, and result reporting in 75 minutes total using a duplex LAMP assay, with sensitivity around 94% and specificity around 73%.²²

The appeal of LAMP is its simplicity: no expensive instruments, minimal training, results that do not require software to interpret. The challenge is standardization. Unlike commercial PCR cartridges where everything comes pre-measured, LAMP assays are mostly laboratory-developed tests, which means performance varies between institutions. Specificity is also uneven across studies, and as with all gene-detection methods, a positive LAMP result does not prove the gene is in a live enterococcus rather than a dead cell or a non-enterococcal organism. Still, for settings where PCR platforms are unaffordable, LAMP represents a meaningful step up from culture-only workflows.

How Resistance Spreads and Why Detection Matters Upstream

Understanding why VRE detection is taken so seriously requires a glimpse at how vancomycin resistance moves between bacteria. The vanA and vanB gene clusters sit on mobile genetic elements that can jump from one organism to another, a process called horizontal gene transfer. This means that a patient colonized with VRE is not just at personal risk; they are a potential source of resistance genes that could transfer to other bacteria, including more dangerous pathogens. Research has even shown that membrane vesicles, tiny bubble-like structures shed by bacteria, can carry vanA and vanB genes and deliver them to neighboring cells.²³

The historical context adds perspective. In Europe, widespread use of a vancomycin-like antibiotic called avoparcin in agriculture created a large reservoir of VRE in farm animals, which then spilled into the human community.²⁴ In the United States, the problem developed primarily within hospitals, driven by heavy vancomycin use in healthcare. Either way, once VRE is established in a facility, it is extraordinarily difficult to eradicate. That reality is what drives the investment in active screening programs, because finding colonized patients before they become sources of transmission is far more effective than reacting to clinical infections after the fact.

A cost-effectiveness analysis of molecular versus conventional detection in intensive care settings estimated that every avoided resistant infection would save several thousand dollars in treatment costs, and that every avoided death from VRE infection represented savings of over a million dollars.²⁵ Those numbers vary by healthcare system, but the economic logic consistently favors early, accurate detection. The upfront cost of screening swabs and lab processing is small relative to the downstream costs of outbreaks, extended hospital stays, and limited treatment options when resistance is missed.